文献速递血栓与止血

PLASMIC评分的外部验证:用于血栓性血小板减少性紫癜诊断与治疗的临床预测工具

External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.
PubMed 文献 · J Thromb Haemost · 2017-11-16

本研究对112例连续住院的疑似血栓性微血管病且行ADAMTS-13检测的患者(含21例TTP)进行PLASMIC评分外部验证。评分预测严重ADAMTS-13缺乏的c统计量为0.94(0.88-0.98);高评分(6-7分) vs 低中评分(0-5分)时,阳性预测值72%、阴性预测值98%、灵敏度90%、特异度92%。低中评分组(0-5分)接受血浆置换与总生存改善无显著相关。

要点

  • PLASMIC评分预测严重ADAMTS-13缺乏的c统计量为0.94(0.88-0.98)。
  • 高评分(6-7分)vs 低中评分(0-5分):阳性预测值72%、阴性预测值98%、灵敏度90%、特异度92%。
  • 低中评分组(0-5分)中,血浆置换与总生存改善无显著相关。

核心结论

  • PLASMIC评分模型对预测严重ADAMTS-13缺乏具有极好的适用性、区分度和校准度。
  • 该临床算法可识别出对经验性治疗缺乏显著反应的患者亚组。

研究设计与样本

  • 独立外部验证研究,纳入112例连续住院的疑似血栓性微血管病且行适当ADAMTS-13检测的患者,其中21例诊断为TTP。

主要发现

  • PLASMIC评分模型预测严重ADAMTS-13缺乏的c统计量为0.94(0.88-0.98)。
  • 以高评分(6-7分) vs 低中评分(0-5分)二分时,模型预测严重ADAMTS-13缺乏的阳性预测值为72%、阴性预测值为98%、灵敏度为90%、特异度为92%。
  • 在低中评分组(0-5分)中,血浆置换与总生存改善无显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Severe ADAMTS-13 deficiency is key to thrombotic thrombocytopenic purpura (TTP) diagnosis. PLASMIC score predicts ADAMTS-13 deficiency in suspected TTP with high discrimination. PLASMIC score is more generalizable with fewer missing data than alternative clinical scores. PLASMIC score identifies a subgroup of patients lacking significant response to plasma exchange. SUMMARY: Background The PLASMIC score was recently published to distinguish patients with severe ADAMTS-13 deficiency from those without for early identification of thrombotic thrombocytopenia purpura (TTP). Objective We performed an independent external validation of the PLASMIC score for clinical prediction of severe ADAMTS-13 deficiency. Patients/Methods We studied an independent cohort of 112 consecutive hospitalized patients with suspected thrombotic microangiopathy and appropriate ADAMTS-13 testing (including 21 patients with TTP diagnosis). Results The PLASMIC score model predicted severe ADAMTS-13 deficiency with a c statistic of 0.94 (0.88-0.98). When dichotomized at high (score 6-7) vs. low-intermediate risk (score 0-5), the model predicted severe ADAMTS-13 deficiency with positive predictive value of 72%, negative predictive value of 98%, sensitivity of 90% and specificity of 92%. In the low-intermediate risk group (score 0-5) there was no significant improvement in overall survival associated with plasma exchange. Conclusions The PLASMIC score model had excellent applicability, discrimination and calibration for predicting severe ADAMTS-13 deficiency. The clinical algorithm allowed identification of a subgroup of patients who lacked a significant response to empiric treatment.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Li A, Khalighi PR, Wu Q, et al. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2017. PMID: 29064619. doi:10.1111/jth.13882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。